At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 129 enrolled
Drug / intervention
Vortioxetine 10 mg +1 moredrug
Likely dose
Vortioxetine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training
In Brief
A Phase 4 clinical trial evaluating Vortioxetine 10 mg and Cognitive training program for Age-related Cognitive Decline. Completed, enrolled 129 participants across 1 site.
Detailed Summary
The purpose of this research study is to examine the potential benefits of vortioxetine in combination with at-home computerized cognitive training program to improve cognition, such as memory, attention, and concentration. This study will compare the effectiveness of vortioxetine plus cognitive training versus placebo plus cognitive training.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-related Cognitive Decline
CountriesUnited States
CollaboratorsQueen's University, Takeda
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedSep 2017
Primary CompletionJan 2019
TodayJul 2026
First PostedSep 5, 2017
Enrollment StartAug 31, 2016
Primary CompletionJan 24, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.8 years ago
Interventions
Vortioxetine 10 mgdrug
Cognitive training programbehavioral
Online training program, 30 minutes a day, 5 times a week